Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON7: Bevacizumab in Ovarian Cancer
NCT00483782Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Apr 2006
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Medical Research Council. Primary endpoints: Progression-Free Survival and Overall Survival. Started Apr 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00483782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483782.